RDHL.TA - RedHill Biopharma Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
236.40
+10.40 (+4.60%)
At close: 5:24PM IDT
Stock chart is not supported by your current browser
Previous Close226.00
Open233.00
Bid239.70 x 400800
Ask240.00 x 100
Day's Range230.50 - 239.30
52 Week Range157.00 - 529.90
Volume177,162
Avg. Volume536,317
Market Cap603.071M
Beta0.15
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Why Redhill Biopharma Ltd. Stock Is Soaring Today
    Motley Fool22 days ago

    Why Redhill Biopharma Ltd. Stock Is Soaring Today

    Redhill's late-stage Crohn's disease drug hits the mark in a late-stage trial.

  • Benzinga23 days ago

    RedHill Earns Long-Awaited Boost On Positive Crohn's Data

    REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) achieved positive top-line results in its Phase 3 study of RHB-104 in Crohn’s disease, according to a Monday press release . What Happened The drug met both primary ...

  • Reuters23 days ago

    RedHill BioPharma has positive results from Crohn's disease trial

    Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104. The study met its primary endpoint and key secondary endpoints, demonstrating the drug's superiority over a placebo in achieving remission of the gastrointestinal disease at week 26, the company said in a statement. "The proportion of patients meeting the primary endpoint was significantly greater in the RHB-104 group compared to placebo," RedHill said.

  • RedHill Gets Two New Patents for Crohn's Disease Candidate
    Zacks2 months ago

    RedHill Gets Two New Patents for Crohn's Disease Candidate

    RedHill Biopharma (RDHL) announces allowances of two new patents from the United States Patent and Trademark Office and the European Patent Office for its Crohn's disease candidate, RHB-104.

  • RedHill Biopharma (RDHL) Catches Eye: Stock Jumps 5.4%
    Zacks2 months ago

    RedHill Biopharma (RDHL) Catches Eye: Stock Jumps 5.4%

    RedHill Biopharma (RDHL) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • RedHill Biopharma (RDHL): Moving Average Crossover Alert
    Zacks2 months ago

    RedHill Biopharma (RDHL): Moving Average Crossover Alert

    RedHill Biopharma Ltd. (RDHL) is looking like an interesting pick from a technical perspective

  • RedHill Biopharma (RDHL) Shares March Higher, Can It Continue?
    Zacks2 months ago

    RedHill Biopharma (RDHL) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in RedHill Biopharma Ltd. (RDHL)

  • Reuters4 months ago

    BRIEF-Swire Pacific Announces Sale Of Residential Unit For HK$120 Million By Redhill Properties

    April 9 (Reuters) - Swire Pacific Ltd: * TO SELL RESIDENTIAL UNIT FOR HK$120 MILLION * CO EXPECTED TO RECORD ATTRIBUTABLE GAIN ON DISPOSAL ABOUT HK$29.1 MILLION * PROPERTY SALE CARRIED OUT THROUGH PROPERTY ...

  • Reuters5 months ago

    Sainsbury's needs year's notice to act on post-Brexit trade deal

    Sainsbury's (SBRY.L), Britain's No.2 supermarket group, needs at least a year's notice to figure out how it would deal with new European Union-UK trading arrangements that would come into play when the Brexit transition period ends, its boss said on Tuesday. Last week, EU leaders approved a transition period to help business adapt after Brexit, allowing talks to start next month on the bloc's future trading relationship with Britain. "Effectively the can's been kicked down the road by 21 months," Sainsbury's Chief Executive Mike Coupe told reporters during a tour of its store in Redhill, southern England.

  • RedHill Biopharma (RDHL) in Focus: Stock Moves 10.2% Higher
    Zacks7 months ago

    RedHill Biopharma (RDHL) in Focus: Stock Moves 10.2% Higher

    RedHill Biopharma (RDHL) was a big mover last session, as the company saw its shares rise more than 10% on the day.

  • American City Business Journals8 months ago

    RedHill teams with Mayo Clinic, MD Anderson on new cancer trial

    Tel-Aviv, Israel-based RedHill Biopharma (RDHL) – which is continuing to build up its U.S. commercial operations based in Raleigh – is teaming with the Mayo Clinic and The University of Texas MD Anderson Cancer Center on a new cancer trial. The new Phase IIa study is for YELIVA – a product candidate RedHill acquired from Apogee Biotechnology back in 2015 – for the treatment of cholangiocarcinoma, or bile duct cancer.

  • American City Business Journals9 months ago

    RedHill grows revenue in third quarter, closes public offering

    According to Tel-Aviv-based RedHill – which opened an office in Raleigh earlier this year with a number of former Salix employees to serve as its head of U.S. commercial operations – its third quarter revenue is from its two initial commercial products, Donnatal and EnteraGam, as well as a third product, Esomeprazole Strontium Delayed-Release (DR) Capsules, which it launched in September . “We expect a decrease in quarterly cash burn rate along with continued revenue growth in 2018,” stated Micha Ben Chorin, chief financial officer of RedHill.

  • RedHill Biopharma Ltd. breached its 50 day moving average in a Bullish Manner : RDHL-IL : November 1, 2017
    Capital Cube10 months ago

    RedHill Biopharma Ltd. breached its 50 day moving average in a Bullish Manner : RDHL-IL : November 1, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for RedHill Biopharma Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics
    Zacks10 months ago

    Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics

    Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics

  • American City Business Journals10 months ago

    RedHill lands new orphan drug designation, looks to grow commercial portfolio

    Benefits of the designation include development incentives and tax credits, as well as potentially a prescription drug user fee waiver and seven-year exclusive marketing period, if MESUPRON is ultimately approved.

  • Reuters11 months ago

    RedHill Biopharma's bowel syndrome drug data fails to impress investors

    RedHill Biopharma Ltd said on Tuesday its drug to treat diarrhea-predominant irritable bowel syndrome met the main goal in a mid-stage study, but the positive data failed to impress investors, sending its U.S.-listed shares lower. The drug, however, did not show statistical significance in improving abdominal pain and overall response in patients - secondary goals in the study. "The study was not designed or meant to show significance in the secondary endpoints ... the results are actually good according to the small sample size," RedHill's Chief Executive Dror Ben-Asher told Reuters.

  • RedHill Biopharma Ltd (RDHL): How Does It Impact Your Portfolio?
    Simply Wall St.11 months ago

    RedHill Biopharma Ltd (RDHL): How Does It Impact Your Portfolio?

    If you are a shareholder in RedHill Biopharma Ltd’s (NASDAQ:RDHL), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • RedHill Biopharma Ltd. breached its 50 day moving average in a Bullish Manner : RDHL-IL : September 20, 2017
    Capital Cube11 months ago

    RedHill Biopharma Ltd. breached its 50 day moving average in a Bullish Manner : RDHL-IL : September 20, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for RedHill Biopharma Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Is RedHill Biopharma Ltd (RDHL) Undervalued?
    Simply Wall St.11 months ago

    Is RedHill Biopharma Ltd (RDHL) Undervalued?

    RedHill Biopharma Ltd (NASDAQ:RDHL), a pharmaceuticals, biotechnology and life sciences company based in Israel, saw significant share price volatility over the past couple of months on the NasdaqCM, rising toRead More...

  • Capital Cubelast year

    RedHill Biopharma Ltd. – Value Analysis (TEL AVIV:RDHL) : August 30, 2017

    Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives RedHill Biopharma Ltd. a score of 43. Our analysis is based on comparing RedHill Biopharma Ltd. with the following peers – Compugen Ltd., Kamada Ltd, XTL Biopharmaceuticals Ltd. and BioCancell Ltd. (CGEN-IL, KMDA-IL, XTLB-IL and BICL-IL). Investment Outlook RedHill Biopharma Ltd. has a fundamental score of 43 ... Read more (Read more...)